Proactiveinvestors USA & Canada GeoVax Labs https://www.proactiveinvestors.com Proactiveinvestors USA & Canada GeoVax Labs RSS feed en Wed, 24 Apr 2019 06:54:56 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[Media files - GeoVax Labs developing a therapy that potentially cures Hepatitis B ]]> https://www.proactiveinvestors.com/companies/stocktube/11804/geovax-labs-developing-a-therapy-that-potentially-cures-hepatitis-b-11804.html Fri, 11 Jan 2019 10:31:00 -0500 https://www.proactiveinvestors.com/companies/stocktube/11804/geovax-labs-developing-a-therapy-that-potentially-cures-hepatitis-b-11804.html <![CDATA[News - GeoVax Labs records SIV risk cuts ]]> https://www.proactiveinvestors.com/companies/news/123389/geovax-labs-records-siv-risk-cuts-123389.html GeoVax Labs (OTCMKTS:GOVX) said on Monday the simian analogue of its human immunodeficiency virus (HIV) vaccine, GOVX-B11, provided a 76% reduction in per exposure risk of simian immunodeficiency virus (SIV) infection in young adult rhesus macaques.

Per exposure risk was assessed over 12 weekly rectal exposures. The study, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), also showed the vaccine providing much better protection for young adult than middle-aged and older macaques.

The test vaccine used a DNA vaccine expressing non-infectious virus-like particles (VLPs) to prime the immune response and a modified vaccinia Ankara (MVA) vaccine, also expressing non-infectious VLPs, to boost the primed response.

The vaccine regimen included two DNA primes at initially and in week 8 followed by two MVA boosts at weeks 16 and 32.

The efficacy of the vaccine was tested at 6 months after the final MVA boost by 12 weekly rectal exposures to a pathogenic SIV given at a dose that infected approximately 30 percent of the unvaccinated animals at each challenge. Animals that were less than 10 years old (estimated human age of about 40) had much better protection than those over 10 years old. The age-dependence for protection was stronger than typically seen for vaccines and likely reflects the HIV target for protective antibody being particularly well-camouflaged.

The human version of the vaccine, GOVX-B11, has undergone clinical testing through the NIAID-supported HIV Vaccine Trials Network (HVTN) in Phase 1 and 2a trials involving about 500 individuals.

These trials have shown the vaccine to have excellent safety and reproducible ability to elicit immune responses. Based on the results of the clinical trials, as well as the current preclinical trial, further evaluation of the GOVX-B11 vaccine in humans will use two DNA primes followed by three MVA boosts with the 16 week rest used in this trial between the last two MVA boosts.

GeoVax shares were up 1.6% at $0.07.

]]>
Mon, 07 Mar 2016 15:16:00 -0500 https://www.proactiveinvestors.com/companies/news/123389/geovax-labs-records-siv-risk-cuts-123389.html
<![CDATA[News - GeoVax partners with Univ. of Georgia to speed up vaccine against Zika virus ]]> https://www.proactiveinvestors.com/companies/news/122131/geovax-partners-with-univ-of-georgia-to-speed-up-vaccine-against-zika-virus-122131.html Biotech company GeoVax Labs (OTCMKTS: GOVX) has teamed up with the University of Georgia to speed up development of a vaccine for the prevention of infection from the Zika virus.

GeorgeVax, established primarily to develop an effective and safe vaccine against HIV-1, ultimately aims to create vaccines for many serious human diseases for which none currently exist, such as Zika. It will use its MVA-VLP vaccine platform in the quest and hopes to rapidly advance a vaccine to human clinical testing.

On February 1, the World Health Organization (WHO) designated the Zika virus and its suspected complications in newborns an international public health emergency. The Zika epidemic, currently in 24 countries in the Americas, is transmitted by the Aedes mosquito and is expected by the WHO to reach most of the Western Hemisphere, infecting up to 4 million people by year's end. 

The Centers for Disease Control and Prevention has issued a travel advisory for people traveling to regions within the Zika virus outbreak, which include popular vacation destinations. Brazil, the site of the 2016 Summer Olympic Games, is included in the advisory. More than 30 cases have been reported in the United States, imported by travelers visiting affected regions.

GeoVax's senior vice president of Research and Development, Farshad Guirakhoo, PhD, will lead the company's effort in developing a Zika virus vaccine. Dr Guirakhoo played pivotal roles in the development and licensure of human vaccines against Flaviviruses including dengue and Japanese encephalitis. His experience and expertise with Flavivirus vaccine development gives the company an advantage over competitors and will shorten the time until a Zika vaccine can be brought to market by GeoVax and its partners, the company said.

In that vein, GeoVax has entered into a Collaborative Research Agreement with the University of Georgia.

Other than mosquito control, no approved preventive or therapeutic products are currently available to fight Zika infections. Public health officials recommend avoiding exposure to Zika, delaying pregnancy, and following basic supportive care after infection. A vaccine is urgently needed to prevent a Zika pandemic.

On Wednesday, media reported an incidence of Zika being spread through sexual contact, in a case in Dallas, United States.

Shares in Atlanta-based GeoVax advanced 21%, or 2 cents, to US$0.10.

 

]]>
Wed, 03 Feb 2016 11:21:00 -0500 https://www.proactiveinvestors.com/companies/news/122131/geovax-partners-with-univ-of-georgia-to-speed-up-vaccine-against-zika-virus-122131.html